Antibacterial Drugs Market Size & Growth Analysis to 2030

The global antibacterial drugs market is expected to grow at the CAGR of 1.2% during 2020-2027. The global antibacterial drugs market is segmented on the basis of drug class and geography. The report on global antibacterial drugs market forecast 2020-2027 (by drug class and geography) provides a detailed overview and predictive analysis of the market.

Antibacterials commonly known as antibiotics are commonly prescribed in modern medicine, with a surge in bacterial infection. The bacterial infection is of major concern especially in cirrhosis patients since it is associated with mortality and morbidity. According to a study held by the WHO, cirrhotic patients associated with urinary tract infection is mainly caused by bacterial sepsis followed by spontaneous bacterial peritonitis (15 – 23%), respiratory tract infection (6 – 10%), and bacteremia (4-9%). High incidence of bacterial infections, vigorous research and development, rise in the geriatric population, and high incidence of nosocomial infections are some of the factors leading to the growth of the antibacterial drugs market. This report on the antibacterial drugs market includes various drugs used in market for treatment along with pipeline analysis of novel drugs coming up in the future.

Antibacterial drugs are being widely used, with an increase in infections caused by aerobic and anaerobic bacteria, gram-positive and negative bacteria. These drugs are obtained from bacteria, molds, or synthesized de novo. The rising prevalence of infectious diseases, research and development in infectious diseases, and government and institutional research support are the key drivers of the antibacterial drugs market. Multi-drug resistant species, patent expiration of the drugs, and penetration of generic drugs might hamper the growth of the antibacterial drugs market. However, with the rise in the geriatric population, nosocomial infections, research, and development for innovative drugs for multi-drug resistant species are some of the major factors driving the antibacterial drugs market.

Market Segment Insights:

The global antibacterial drugs market is majorly segmented by drug class type into beta-lactams, aminoglycosides, sulfonamides, tetracyclines, quinolones, phenicols, macrolides, and miscellaneous antibacterials. Beta-lactams occupies the largest share market of the global antibacterial drugs market followed by the quinolones. These drug classes will decline in the future during the forecast period, due to leading brands losing their market exclusivity, the surge in the number of drug-resistant bacterial strains and entry of generics in the market.

Global Antibacterial drugs Market Segmentation:

By Drug Class:

• B-lactam
• Quinolones
• Macrolides
• Tetracyclines
• Aminoglycosides
• Sulfonamides
• Phenicols
• Others

By Route of Administration:

• Enteral
• Parenteral
• Others

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Sales

By Geography, 2018-2027 ($ Million)

• North America (U.S. & Canada)
• Europe (U.K., Germany & Rest of Europe)
• Asia Pacific (China, Japan, and Rest of APAC)
• Latin America (Brazil, Mexico and Rest of LATAM)
• Middle East and Africa (UAE, Saudi Arabia, South Africa)

Regional Insights:

Asia Pacific dominates the antibacterial drugs market in 2019 and is anticipated to be the fastest growing market in the forecast period. Asia Pacific is occupying the largest market share, as it is driven large base population infected by varied bacterial infection such as tuberculosis, pneumonia etc., rising disposable income, improving healthcare structure. Next followed up market is North America and Europe, the regions show slow growth in the forecast period due to generic entry and stringent regulatory policies.

Market Competition Assessment:

Key players in the antibacterial drugs market are Novartis AG, Pfizer Inc., Merck & Co., Johnson & Johnson Limited, Astra Zeneca plc, Abbott Laboratories, Sanofi SA, Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Bayer AG and others.

List of Key Companies:

• Pfizer Inc.
• Novartis AG
• Merck & Co.
• Astra Zeneca plc
• Johnson & Johnson Limited
• Abbott Laboratories
• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb Company
• Bayer AG
• GlaxoSmithKline plc
• Others